BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26249025)

  • 1. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy.
    Jung KS; Kim SU; Song K; Park JY; Kim DY; Ahn SH; Kim BK; Han KH
    Hepatology; 2015 Dec; 62(6):1757-66. PubMed ID: 26249025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B.
    Jeon MY; Lee HW; Kim SU; Kim BK; Park JY; Kim DY; Han KH; Ahn SH
    Liver Int; 2018 Apr; 38(4):676-686. PubMed ID: 28865176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
    Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
    J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study.
    Seo YS; Jang BK; Um SH; Hwang JS; Han KH; Kim SG; Lee KS; Kim SU; Kim YS; Lee JI
    Oncotarget; 2017 Dec; 8(68):113213-113224. PubMed ID: 29348900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients.
    Lee HW; Ahn SH
    World J Gastroenterol; 2016 Oct; 22(37):8314-8321. PubMed ID: 27729738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
    Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
    Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
    Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
    Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
    Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
    Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China.
    Lou T; Li B; Xiong P; Jin C; Chen Y
    J Viral Hepat; 2021 Oct; 28(10):1373-1380. PubMed ID: 34218498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Hepatitis B Virus DNA Level and Follow-up Interval With Hepatocellular Carcinoma Recurrence.
    Wang W; Tian SL; Wang H; Shao CC; Wang YZ; Li YL
    JAMA Netw Open; 2020 Apr; 3(4):e203707. PubMed ID: 32338753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
    Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
    Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals.
    Ji JH; Park SY; Son WJ; Shin HJ; Lee H; Lee HW; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK
    J Viral Hepat; 2021 Jun; 28(6):951-958. PubMed ID: 33763928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
    J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma.
    Huang L; Li J; Lau WY; Yan J; Zhou F; Liu C; Zhang X; Shen J; Wu M; Yan Y
    J Gastroenterol Hepatol; 2012 Jan; 27(1):158-64. PubMed ID: 21871026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis.
    Shin SH; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
    Liver Int; 2015 Mar; 35(3):1054-62. PubMed ID: 24930484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
    Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma.
    Lao XM; Luo G; Ye LT; Luo C; Shi M; Wang D; Guo R; Chen M; Li S; Lin X; Yuan Y
    Liver Int; 2013 Apr; 33(4):595-604. PubMed ID: 23402625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher efficacy of antiviral therapy after major hepatectomy in patients with hepatitis B virus-related hepatocellular carcinoma of less than 3 cm.
    Zhang ZY; Zhou ZQ; Zhou GW
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1116-24. PubMed ID: 25003747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy.
    Lee HW; Yoo EJ; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Han KH
    Am J Gastroenterol; 2014 Aug; 109(8):1241-9. PubMed ID: 24957159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.